ALAPIS S.A. announces that pursuant to its business plan and via the use of part of the proceeds that were injected from the recent share capital increase via rights issue, the Company acquired the shares of "LAMDA APPLIED PHARMACEUTICALS LABORATORY FOR APPLIED RESEARCH S.A.". The acquisition value of the shares of LAMDA APPLIED amounted to 475,000 Euros.
LAMDA APPLIED was founded in 2002 and has marked sustained growth pattern ever since. LAMDA APPLIED was established in order to get involved in the applied research for the development of generics. In specific, it is a pharmaceutical laboratory for quality control, as well as for the planning, research and development of pharmaceutical patent medicine in the area of the Lavrio Technological and Cultural Park or in any other suitable place, which will contain a full Chemistry lab, appropriately equipped and staffed in order to provide all necessary quality control functions for the above mentioned purposes based on Good Laboratory Practices, as they are determined by the Greek authorities and will be active, amongst others, in the quality control of pharmaceutical products which are either in circulation or in the development stage, will control and validate analysis methods for pharmaceutical products.
Staffed with 20 specialized scientists, the Company developed and approved over one hundred products in Greece as well as in other European countries. The high quality standards of its products and services have made the Company a partner of some of the largest Greek and multinational companies. Within the framework of its activities today it offers additional services on:
* Formulation
* Patent Status Report
* NP, MRP, DCP
* Eudravigilance